NASDAQ: MBX · Life Sciences · 5 alerts · CIK 1776111
Share price
$53.12Close, Nov 16
Market cap
$2.64B
Shares outstanding
49.66MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All MBX Biosciences, Inc. filings on SEC EDGAR ↗
MBX Biosciences Chairman, President and CEO Steven L. Hoerter Sells $268K of Stock
Steven L. Hoerter, Chairman, President and CEO, sold 4,893 shares of MBX Biosciences, Inc. at $54.82 a share, worth $268K in total on Nov 10, 2026. Shares held after the trade: 78,045 (-5.9%).
MBX Biosciences reported a significant increase in operating expenses for the nine months ended September 30, 2026, with research and development costs rising to $81.5 million. The company's cash and marketable securities position strengthened to approximately $481.6 million following public offerings, while the accumulated deficit grew to $347.5 million. As of November 5, 2026, the company had 49,656,265 shares of common stock outstanding.
MBX Biosciences reported third quarter 2026 financial results, highlighting the initiation of its pivotal Phase 3 oPTimize trial for canvuparatide in hypoparathyroidism. The company ended the quarter with $481.6 million in cash and investments, which is expected to fund operations into 2029.
Term
Q3 2026
“The third quarter marked an important milestone for MBX with the initiation of our pivotal Phase 3 oPTimize trial of once-weekly canvuparatide, a potential best-in-class PTH replacement therapy.”
Steve Hoerter, Chairman and Chief Executive Officer
“With a strong balance sheet and cash runway into 2029, we believe we are well positioned to advance canvuparatide through pivotal development while continuing to invest in our growing obesity portfolio.”
Steve Hoerter, Chairman and Chief Executive Officer
MBX Biosciences CMO Salomon Azoulay Sells $20.1K of Stock
Salomon Azoulay, CMO, sold 373 shares of MBX Biosciences, Inc. at $53.96 a share, worth $20.1K in total on Nov 4, 2026. Shares held after the trade: 14,026 (-2.6%).
MBX Biosciences appointed Peter Radovich to its Board of Directors as a Class I director, effective October 20, 2026. In connection with his appointment, Mr. Radovich received an initial grant of non-qualified stock options for 18,200 shares and will receive cash compensation according to the company's non-employee director compensation policy.